Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.
暂无分享,去创建一个
[1] P A Poole-Wilson,et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.
[2] P. Amouyel,et al. Unhealthy effects of atmospheric temperature and pressure on the occurrence of myocardial infarction and coronary deaths. A 10-year survey: the Lille-World Health Organization MONICA project (Monitoring trends and determinants in cardiovascular disease). , 1999, Circulation.
[3] P. Poole‐Wilson,et al. Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study , 1999, European journal of heart failure.
[4] P. Poole‐Wilson,et al. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. , 1998, Journal of cardiac failure.
[5] A. Sjølie,et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes , 1998, The Lancet.
[6] T. Mets,et al. Drug-Induced Orthostatic Hypotension in the Elderly , 1997, Drug safety.
[7] N. Chaturvedi. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria , 1997, The Lancet.
[8] G. Paolisso,et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. , 1997, Diabetes & metabolism.
[9] M. Packer. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? , 1996, Journal of the American College of Cardiology.
[10] P. Poole‐Wilson,et al. ACE inhibitors for heart failure: a question of dose. , 1994, British heart journal.
[11] J. Hansen,et al. Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. , 1994, European heart journal.
[12] G. Murray,et al. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .
[13] Therapy Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure , 1993, The Lancet.
[14] W. Stevenson,et al. Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1993, The American journal of cardiology.
[15] M. Mondal,et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. , 1993, The Journal of the Association of Physicians of India.
[16] K. Schulte,et al. Clinical Pharmacokinetics of Angiotensin Converting Enzyme (ACE) Inhibitors in Renal Failure , 1993, Clinical pharmacokinetics.
[17] B. Materson,et al. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors. , 1992, Archives of internal medicine.
[18] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[19] M. Packer,et al. Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system. , 1986, Circulation.